OrbiMed Discloses 14.0% Stake in ADARx Pharmaceuticals After IPO

OrbiMed Advisors LLC has disclosed a 14.0% stake in ADARx Pharmaceuticals, Inc. (NASDAQ: ADRX), making the healthcare-focused investment firm one of the largest holders of the newly public drug developer's common stock.

The firm filed a Schedule 13D with the SEC on Oct. 2, 2026. The disclosure follows ADARx's initial public offering on Sept. 28, 2026, in which OrbiMed-led purchasers bought shares at $17 per share and converted preferred stock into common shares.

Investment intent, not control

OrbiMed states plainly why it accumulated the position. "The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control," the filing reads.

The firm also reserves flexibility on both sides of the trade. OrbiMed says it may buy additional shares or sell existing ones as it monitors ADARx's progress and market conditions. That language matters for investors tracking ADRX supply: a 14.0% holder with stated intent to adjust its position can move the register either way.

The stock traded down 6.60% around the time of the disclosure.

Lock-up and registration rights

In connection with the IPO, OrbiMed funds and two OrbiMed-affiliated directors agreed to a 180-day lock-up. The agreement restricts sales, hedging transactions, and demand registrations during that window.

Once the lock-up expires, the group holds tools to exit efficiently. Under an investors' rights agreement, OrbiMed carries demand registration rights, piggyback registration rights, and Form S-3 registration rights. These provisions could facilitate future share sales into the public market once permitted.

The structure is standard for a crossover investor that backed the company privately and doubled down at the IPO. OrbiMed's stake combines freshly purchased IPO shares at $17 each with common stock obtained through conversion of previously held preferred shares.

Who is OrbiMed

OrbiMed Advisors LLC is a Delaware limited liability company and a registered investment adviser managing healthcare-focused funds. The firm invests across venture capital, private equity, and public equities, with a long track record in biotech and life sciences.

OrbiMed has backed numerous drug developers from early-stage financing through IPOs and follow-on offerings. Its willingness to hold a double-digit stake after ADARx's debut signals continued conviction in the company's clinical and commercial trajectory, at least through the lock-up period.

The immediate question for ADRX holders is timing: 180 days from the late-September IPO, OrbiMed's contractual restrictions lift, and the firm's stated openness to buying or selling — combined with its registration rights — will give it broad latitude to act on its position.